his trial is being conducted at five University Hospital Centres in China in association with a Chinese biotech, Alliancells Bioscience Corporation. The trial seeks to investigate the effect of donated umbilical cord blood on patients with liver cirrhosis. Participants will be divided into a control group where they will receive standard treatment, and a test group where they will receive four intravenous injections (IV injections) of donated cord blood over a period of one year. The participants will be monitored for three years for complications and for changes in liver function. The trial expects to enrol 320 participants by October 2015.